Abstract:Background: Mpox was first identified in the Democratic Republic of the Congo (DRC) in 1970. In 2023, a historic outbreak of mpox occurred in the country, continuing into 2024. Over 14 000 cases and 600 deaths were reported in 2023 alone, representing a major increase from previous outbreaks. The modified vaccinia Ankara vaccine (brand names JYNNEOS, Imvamune, and Imvanex) was used in the 2022 mpox outbreak in the USA and Europe. However, at the time of the study, vaccination had not been made available in the DRC. We aimed to inform policy and decision makers on the potential benefits of, and resources needed, for mpox vaccination campaigns in the DRC by providing counterfactual scenarios evaluating the short-term effects of various vaccination strategies on mpox cases and deaths, if such a vaccination campaign had been undertaken before the 2023-24 outbreak. Methods: A dynamic transmission model was used to simulate mpox transmission in the DRC, stratified by age (<5, 5-15, and >15 years) and province. The model was used to simulate potential vaccination strategies, varying by age and region (endemic provinces, non-endemic provinces with historic cases, and all provinces) assessing the effect the strategies would have on deaths and cases in an epidemic year similar to 2023. In addition, we estimated the number of vaccine doses needed to implement each strategy. Findings: Without vaccination, our model predicted 14 700 cases and 700 deaths from mpox over 365 days. Vaccinating 80% of all children younger than 5 years in endemic regions led to a 27% overall reduction in cases and a 43% reduction in deaths, requiring 10·5 million vaccine doses. Vaccinating 80% of all children younger than 5 years in all regions led to a 29% reduction in cases and a 43% reduction in deaths, requiring 33·1 million doses. Vaccinating 80% of children aged 15 years or younger in endemic provinces led to a 54% reduction in cases and a 71% reduction in deaths, requiring 26·6 million doses. Interpretation: When resources are limited, vaccinating children aged 15 years or younger, or younger than 5 years, in endemic regions of the DRC would be the most efficient use of vaccines. Further research is needed to explore long-term effects of a one-time or recurrent vaccination campaign. Funding: Canadian Institutes of Health Research, Canadian International Development Research Centre, US Department of Defense (Defense Threat Reduction Agency, Mpox Threat Reduction Network), Global Affairs Canada (Weapons Threat Reduction Program), US Department for Agriculture (Agriculture Research Service, Non-Assistance Cooperative Agreement).

First Nationwide Mpox Vaccination Program in the Republic of Korea: Implications for an Enhanced Public Health Response

Monkeypox Vaccination in the Republic of Korea: Identifying the High-Risk Target Group

Age-Related Antibody Response to Orthopoxviruses and Implications for Public Health Measures: Insights from a South Korean Study

Who gets COVID-19 booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea

Clinical Features of Mpox Patients in Korea: A Multicenter Retrospective Study

Clinical presentation, viral shedding, and neutralizing antibody responses of mpox cases in South Korea: Single center experience

COVID-19 Outbreak in Daegu City, Korea and Response to COVID-19: How Have We Dealt and What Are the Lessons?

COVID-19 outbreak response at a nursing hospital in South Korea in the post-vaccination era, including an estimation of the effectiveness of the first shot of the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1-S)

Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023

Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in Korea: interim analysis

Modelling vaccination approaches for mpox containment and mitigation in the Democratic Republic of the Congo

Establishment of Safety Monitoring System for Vaccines Not Included in the National Immunization Program in Korea

Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea

Development of Smallpox Antibody Testing and Surveillance Following Smallpox Vaccination in the Republic of Korea

Prioritization of Vaccines for Introduction in the National Immunization Program in the Republic of Korea

Establishing a Framework for Evaluating the Effectiveness of Vaccines Targeting National Vaccination Programs

Safety and Effectiveness of LC16m8 for Pre-Exposure Prophylaxis against mpox in a High-Risk Population: An Open-Label Randomized Trial

The Korean Influenza National Immunization Program: History and Present Status

Democratic Republic of the Congo: a strengthened response to mpox could help revitalise the country's healthcare system

Effectiveness of a single dose of JYNNEOS vaccine in real world: A systematic review and meta-analysis

Effective Vaccination and Education Strategies for Emerging Infectious Diseases Such as COVID-19